Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Valproinsyra

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Valproinsyra Testmiljö

Valproinsyra

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Ibarra M, Vázquez M, Fagiolino P, Derendorf H. Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn. 2013;40:479-86.

  2. Park HM, Kang SS, Lee YB, Shin DJ, Kim ON, Lee SB et al. Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther. 2002;27:419-25.

  3. Smith RL, Haslemo T, Refsum H, Molden E. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data. Eur J Clin Pharmacol. 2016;72(9):1099-104.

  4. Absenor (valproic acid). Summary of Product Characteristics. Swedish Medical Products Agency; 2018.

  5. Ergenyl (valproic acid). Summary of Product Characteristics. Swedish Medical Products Agency; 2018.

  6. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-14.

  7. Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12:e32-43.

  8. Noai M, Soraoka H, Kajiwara A, Tanamachi Y, Oniki K, Nakagawa K et al. Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. Acta Neurol Scand. 2016;133(3):216-23.

  9. Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K et al. Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia. 2013;54(6):983-9.

  10. Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K, Itoh K et al. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res. 2012;101(3):202-9.

  11. Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC et al. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine (Baltimore). 2014;93(11):e66.

  12. Läkemedelsverket. Valproat: Nya användningsbegränsningar; implementering av graviditetspreventionsprogrammet. Läkemedelsverket [www]. [cited 2018-09-28].

  13. Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures. European Medicines Agency (EMA) [www]. [updated 2024-01-12, cited 2024-01-19].

  14. Verrotti A, D'Egidio C, Mohn A, Coppola G, Parisi P, Chiarelli F. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia. 2011;52:199-211.

  15. Isojärvi JI, Löfgren E, Juntunen KS, Pakarinen AJ, Päivänsalo M, Rautakorpi I et al. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology. 2004;62:247-53.

  16. Ocek L, Tarhan H, Uludağ FI, Sarıteke A, Köse C, Colak A et al. Evaluation of sex hormones and sperm parameters in male epileptic patients. Acta Neurol Scand. 2018;137(4):409-416.

  17. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Ibarra M, Vázquez M, Fagiolino P, Derendorf H. Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn. 2013;40:479-86.
  2. Park HM, Kang SS, Lee YB, Shin DJ, Kim ON, Lee SB et al. Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther. 2002;27:419-25.
  3. Smith RL, Haslemo T, Refsum H, Molden E. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data. Eur J Clin Pharmacol. 2016;72(9):1099-104.
  4. Absenor (valproic acid). Summary of Product Characteristics. Swedish Medical Products Agency; 2018.
  5. Ergenyl (valproic acid). Summary of Product Characteristics. Swedish Medical Products Agency; 2018.
  6. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-14.
  7. Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12:e32-43.
  8. Noai M, Soraoka H, Kajiwara A, Tanamachi Y, Oniki K, Nakagawa K et al. Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. Acta Neurol Scand. 2016;133(3):216-23.
  9. Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K et al. Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia. 2013;54(6):983-9.
  10. Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K, Itoh K et al. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res. 2012;101(3):202-9.
  11. Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC et al. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine (Baltimore). 2014;93(11):e66.
  12. Läkemedelsverket. Valproat: Nya användningsbegränsningar; implementering av graviditetspreventionsprogrammet. Läkemedelsverket [www]. [cited 2018-09-28].
  13. Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures. European Medicines Agency (EMA) [www]. [updated 2024-01-12, cited 2024-01-19].
  14. Verrotti A, D'Egidio C, Mohn A, Coppola G, Parisi P, Chiarelli F. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia. 2011;52:199-211.
  15. Isojärvi JI, Löfgren E, Juntunen KS, Pakarinen AJ, Päivänsalo M, Rautakorpi I et al. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology. 2004;62:247-53.
  16. Ocek L, Tarhan H, Uludağ FI, Sarıteke A, Köse C, Colak A et al. Evaluation of sex hormones and sperm parameters in male epileptic patients. Acta Neurol Scand. 2018;137(4):409-416.
  17. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]